AI-Generated Summary

Hanmi Pharmaceutical announced a global technology transfer deal with Gilead Sciences for its oral absorption enhancer, Encequidar, leading to a significant rise in Hanmi's stock. The agreement grants Gilead exclusive worldwide rights and includes upfront, milestone, and royalty payments to Hanmi and Health Hope Pharma, with the initial payment expected to ease Hanmi's future earnings uncertainty.

In a nutshell

This deal highlights the strategic importance of licensing agreements for pharmaceutical companies to expand market reach and leverage innovative platforms. For Hanmi, it provides significant financial upside and validates its technological assets, while for Gilead, it potentially enhances its therapeutic pipeline.

Source: The Tribune